Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Inclusion criteria

• Diagnosis of moderate to severe chronic plaque psoriasis
• Active psoriasis, despite topical therapies

Exclusion criteria

• Other active skin diseases or skin infections
• Prior exposure to any anti-TNF therapy
• Subject has other active skin diseases
• Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other systemic PS therapies)
• Poorly controlled medical conditions
• History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease.
• History of cancer or lymphoproliferative disease
• History of active TB or listeriosis, or persistent chronic or active infections
• Known to have immune deficiency or is immunocompromised
• Clinically significant abnormal laboratory test results
• Erythrodermic psoriasis or generalized pustular psoriasis